18 NOV 2021
14:30 CET

The ABC of ADCs

The ABC of ADCs

About event

Antibody drug conjugates (ADCs) have the potential to revolutionize conventional cancer treatment. They comprise of monoclonal antibodies that selectively deliver potent cytotoxic drugs. Each component of the ADC must be optimized to fully realize the goal of a targeted therapy with improved efficacy and tolerability. Advancements over the past several decades have led to a new generation of ADCs with balanced stability and highly potent cytotoxic agents. Although challenges remain, recent clinical successes have generated intense interest in this therapeutic class. World BI’s The ABC of ADCs discusses the characterization challenges of these ADCs and also their role in targeted tumor therapy.

Enhance Engagement

Data-Driven Approach

Can Be Tracked Easily

Real-Time Customizations

Cross Country Networking

Optimized Return on Investment


Meet our Professionals


Shruthi Bharadwaj, Ph.D

Strategic and Technical Advisor Chief Data and AI Office



Rajkumar Ganesan

Director – Antibody Engineering (Bispecifics and CAR-T)

The Janssen Pharmaceutical Companies of Johnson & Johnson


Tomi Sawyer

Chief Drug Hunter & President

Maestro Therapeutics


Sara Colombetti

Global Head of Oncology Discovery Pharmacology

Roche Innovation Center Zurich


Namshik Han, PhD

Head of Artificial Intelligence

Milner Therapeutics Institute University of Cambridge


Vast number of different speeches
and activities

Newsletter Sign Up

No Spam - Only latest news, price and activity updates

Who will attend

Delegates Will Include VPs, Global Heads, Directors and Managers.

Chief Scientific Officers
Research and Development
Chief Executive Officers
Corporate Development

Register to Event now!


  • WorldBI, Office 7, 35-37 Ludgate Hill, London. EC4M 7JN
  • info@worldbigroup.com
  • 00 44 (0) 20 3129 8222
  • 10:00 - 18:00